热门资讯> 正文
强生在估值和制药潜力方面升级富国银行
2025-10-03 20:12
- Wells Fargo upgraded Johnson & Johnson JNJ) to over-weight from equal weight saying that the healthcare giant is attractively priced with pharmaceutical tariff risks and drug pricing concerns in the rear-view mirror.
- The bank upped its price target to $212 from $170 (~14% upside based on Oct. 2 close).
- Analyst Larry Biegelsen said that J&J's current share price provides an attractive entry point given the potential upside to its pharma business.
- In that segment, he expects better growth in 2026 than 2025, and in 2027, to exceed 2026's growth.
- Biegelsen added that in light of Pfizer's (PFE) announcement on Sept. 30 of a deal with the Trump administration to supply its drugs at a discount to US consumers, he expects other pharmas to follow suit.
More on Johnson & Johnson
- Johnson & Johnson (JNJ) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
- Johnson & Johnson (JNJ) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
- Johnson & Johnson: All-Time Highs In Sight After Raised Guidance And A Technical Breakout
- Nanobiotix gains after early-stage trial data for J&J-partnered cancer drug
- INCY and ABBV lead S&P 500 healthcare gainers in Q3; MOH and ALGN lag
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
